Key result
Incorporating novel biomarkers into multi-biomarker strategies improves post-MI risk stratification and prognosis.
Why the study?
Despite advances in diagnosis and treatment, acute myocardial infarction remains a leading cause of morbidity and mortality, requiring early identification of high-risk patients through biomarker measurement to improve risk stratification and guide individualized therapy.
Do cardiac biomarkers and artificial intelligence algorithms improve risk stratification and prognostic assessment in patients with acute myocardial infarction?
Design
Review article
Authors
Loading...
May support multi-biomarker panels for AMI risk stratification; leaves open clinical adoption pending prospective validation.
Do cardiac biomarkers and artificial intelligence algorithms improve risk stratification and prognostic assessment in patients with acute myocardial infarction?
Multi-biomarker strategies and artificial intelligence algorithms show promise in improving risk stratification and prognostic assessment for patients with acute myocardial infarction.
Stătescu et al. (2022) studied this question. Novel biomarkers related to myocardial infarction pathophysiology can enhance risk stratification and prognosis when used in multi-biomarker strategies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: